ADVANCES IN ANTI-TUBERCULOSIS DRUGS

  • Sapna Pradhan Dept of Pharmacology Army College of Medical Sciences Delhi Cantt-110010
  • A G Mathur Dept of Pharmacology Army College of Medical Sciences Delhi Cantt-110010
  • Amol Patil Dept of Pharmacology Army College of Medical Sciences Delhi Cantt-110010

Abstract

Despite the introduction 40 years ago of the inexpensive and effective four-drug (isoniazid, rifampicin, pyrazinamide and ethambutol) treatment regimen, tuberculosis (TB) continues to cause considerable morbidity and mortality worldwide. For the first time since the 1960s, new and novel drugs and regimens for all forms of TB are emerging. Such regimens are likely to utilize both repurposed drugs and new chemical entities, and several of these regimens are now progressing through clinical trials. This article covers current concepts and recent advances in TB drug discovery and development.

Key Words: MDR-TB, XDR-TB, TDR-TB, Bedaquiline, Delamanid

 

Downloads

Download data is not yet available.
Statistics
51 Views | 60 Downloads
How to Cite
Pradhan, S., Mathur, A., & Patil, A. (2014). ADVANCES IN ANTI-TUBERCULOSIS DRUGS. Journal of Drug Delivery and Therapeutics, 4(5), 69-73. https://doi.org/10.22270/jddt.v4i5.965